{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:45:56Z","timestamp":1793202356823,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.bcp.2023.115735","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T11:21:58Z","timestamp":1691666518000},"page":"115735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Effect of pharmacological heart failure drugs and gene therapy on Danon's cardiomyopathy"],"prefix":"10.1016","volume":"215","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9143-0943","authenticated-orcid":false,"given":"Dor","family":"Yadin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tali","family":"Guetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Petrover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronny","family":"Alcalai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Seidman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E","family":"Seidman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efrat","family":"Ofek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Kornowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Hochhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Arad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2023.115735_b0005","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1212\/WNL.31.1.51","article-title":"Lysosomal glycogen storage disease with normal acid maltase","volume":"31","author":"Danon","year":"1981","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.bcp.2023.115735_b0010","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/nan.12587","article-title":"Danon disease: review of natural history and recent advances","volume":"46","author":"Cenacchi","year":"2020","journal-title":"Neuropathology and Applied Neurobiolo-gy"},{"issue":"286","key":"10.1016\/j.bcp.2023.115735_b0015","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijcard.2019.01.020","article-title":"Danon disease: Gender differences in presentation and outcomes","volume":"1","author":"Brambatti","year":"2019","journal-title":"Int J Cardiol."},{"issue":"6798","key":"10.1016\/j.bcp.2023.115735_b0020","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/35022604","article-title":"Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease)","volume":"406","author":"Nishino","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2023.115735_b0025","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1146\/annurev-physiol-021014-071649","article-title":"Lysosomal physiology","volume":"77","author":"Xu","year":"2015","journal-title":"Annu. Rev. Physiol."},{"issue":"17","key":"10.1016\/j.bcp.2023.115735_b0030","doi-asserted-by":"crossref","first-page":"e018829","DOI":"10.1161\/JAHA.120.018829","article-title":"LAMP2 cardiomyopathy: consequences of impaired autophagy in the heart","volume":"10","author":"Alcalai","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.bcp.2023.115735_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115229","article-title":"Autophagy guided interventions to modify the cardiac phenotype of Danon disease","author":"Yadin","year":"2022","journal-title":"Biochemical Pharmacology 204"},{"key":"10.1016\/j.bcp.2023.115735_b0040","unstructured":"A Clinical Study Evaluating a Recombinant Adeno-Associated Virus Serotype 9 (rAAV9) Capsid Containing the Human Lysosome-Associated Membrane Protein 2 Isoform B (LAMP2B) Transgene (RP-A501; AAV9.LAMP2B) in Male Patients With DD. NCT number: NCT03882437."},{"issue":"4","key":"10.1016\/j.bcp.2023.115735_b0045","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa033349","article-title":"Glycogen storage diseases presenting as hypertrophic cardiomyopathy","volume":"352","author":"Arad","year":"2005","journal-title":"New England Journal of Medi-cine"},{"key":"10.1016\/j.bcp.2023.115735_b0050","doi-asserted-by":"crossref","unstructured":"Oudit, Gavin Y., et al. \u201cAngiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice.\u201d Cardiovascular research 75.1 (2007): 29-39. 10.1016\/j.cardiores.2007.04.007.","DOI":"10.1016\/j.cardiores.2007.04.007"},{"issue":"1","key":"10.1016\/j.bcp.2023.115735_b0055","article-title":"Regulation of diabetic cardiomyopathy by caloric restriction is mediated by intracellular signaling pathways involving \u201cSIRT1 and PGC-1\u03b1\u201d","volume":"17","author":"Waldman","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.bcp.2023.115735_b0060","doi-asserted-by":"crossref","unstructured":"Seeland, Ute, et al. \u201cEffect of ramipril and furosemide treatment on interstitial remodeling in post-infarction heart failure rat hearts.\u201d Journal of molecular and cellular cardiology 34.2 (2002): 151-163. 10.1006\/jmcc.2001.1497.","DOI":"10.1006\/jmcc.2001.1497"},{"key":"10.1016\/j.bcp.2023.115735_b0065","doi-asserted-by":"crossref","unstructured":"Cezar, Marcelo DM, et al. \u201cEarly spironolactone treatment attenuates heart failure development by improving myocardial function and reducing fibrosis in spontaneously hypertensive rats.\u201d Cellular Physiology and Biochemistry 36.4 (2015): 1453-1466. 10.1159\/000430310.","DOI":"10.1159\/000430310"},{"key":"10.1016\/j.bcp.2023.115735_b0070","doi-asserted-by":"crossref","unstructured":"Jelinek, Marisa, et al. \u201cGenetic background dominates the susceptibility to ventricular arrhythmias in a murine model of \u03b2-adrenergic stimulation.\u201d Scientific Reports 8.1 (2018): 1-10. | DOI:10.1038\/s41598-018-20792-5.","DOI":"10.1038\/s41598-018-20792-5"},{"key":"10.1016\/j.bcp.2023.115735_b0075","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ijcard.2015.10.126","article-title":"Macrophages dictate the progression and manifestation of hypertensive heart disease","volume":"203","author":"Kain","year":"2016","journal-title":"International Journal of Cardiology"},{"key":"10.1016\/j.bcp.2023.115735_b0080","doi-asserted-by":"crossref","unstructured":"Kurtzwald-Josefson, Efrat, et al. \u201cViral delivered gene therapy to treat catecholaminergic polymorphic ventricular tachycardia (CPVT2) in mouse models.\u201d Heart Rhythm 14.7 (2017): 1053-1060. 10.1016\/j.hrthm.2017.03.025.","DOI":"10.1016\/j.hrthm.2017.03.025"},{"issue":"3","key":"10.1016\/j.bcp.2023.115735_b0085","doi-asserted-by":"crossref","first-page":"744","DOI":"10.21037\/cdt-20-883","article-title":"Angiotensin II and hypoxia induce autophagy in cardiomyocytes via activating specific protein kinase C subtypes","volume":"11","author":"Xiao","year":"2021","journal-title":"Cardiovascular Diagnosis and Therapy"},{"issue":"2","key":"10.1016\/j.bcp.2023.115735_b0090","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/jvim.15454","article-title":"The renin-angiotensin-aldosterone system and its suppression","volume":"33","author":"Ames","year":"2019","journal-title":"J. Vet. Intern. Med."},{"issue":"11","key":"10.1016\/j.bcp.2023.115735_b0095","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.hrthm.2010.07.004","article-title":"Optimizing catecholaminergic polymorphic ventricular tachycardia therapy in calsequestrin-mutant mice","volume":"7","author":"Katz","year":"2010","journal-title":"Heart Rhythm"},{"issue":"4","key":"10.1016\/j.bcp.2023.115735_b0100","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1530\/JME-16-0086","article-title":"The role of autophagy in angiotensin II-induced pathological cardiac hyper-trophy","volume":"57","author":"Zhou","year":"2016","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.bcp.2023.115735_b0105","doi-asserted-by":"crossref","unstructured":"Dittrich, Sven, et al. \u201cEffect and safety of treatment with ACE-inhibitor Enalapril and \u03b2-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy-a randomized, double-blind, placebo-controlled trial.\u201d Orphanet journal of rare diseases 14.1 (2019): 1-13. 10.1186\/s13023-019-1066-9.","DOI":"10.1055\/s-0038-1628322"},{"issue":"6","key":"10.1016\/j.bcp.2023.115735_b0110","first-page":"e003117","article-title":"Clinical profile of cardiac involvement in Danon disease: a multicenter European registry","volume":"13","author":"Lotan","year":"2020","journal-title":"Circulation: Ge-nomic and Precision Medicine"},{"key":"10.1016\/j.bcp.2023.115735_b0115","doi-asserted-by":"crossref","unstructured":"Greenberg, Barry, et al. \u201cResults from first-in-human clinical trial of RP-A501 (AAV9: LAMP2B) gene therapy treatment for Danon disease.\u201d Circulation 144.Suppl_1 (2021): A10727-A10727. 10.1161\/circ.144.suppl_1.10727.","DOI":"10.1161\/circ.144.suppl_1.10727"},{"key":"10.1016\/j.bcp.2023.115735_b0120","first-page":"86","article-title":"Impaired mitophagy facilitates mitochondrial damage in Danon disease","volume":"108","author":"Hashem","year":"2017"},{"key":"10.1016\/j.bcp.2023.115735_b0125","doi-asserted-by":"crossref","unstructured":"Hashem, Sherin I., et al. \u201cBrief report: oxidative stress mediates cardiomyocyte apoptosis in a human model of Danon disease and heart failure.\u201d Stem cells 33.7 (2015): 2343-2350. 10.1002\/stem.2015.","DOI":"10.1002\/stem.2015"},{"key":"10.1016\/j.bcp.2023.115735_b0130","unstructured":"Heidenreich, Paul A., et al. \u201c2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.\u201d Journal of the American College of Cardiology 79.17 (2022): 1757-1780. 10.1161\/CIR.0000000000001062."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522300326X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522300326X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:20:12Z","timestamp":1762096812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000629522300326X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":26,"alternative-id":["S000629522300326X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115735","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of pharmacological heart failure drugs and gene therapy on Danon's cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115735","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115735"}}